When cannabis is indicated to treat anxiety

The relationship between infection and conventional antibiotics

Could CBD be useful in the fight versus resistant bacterial pressures? The results from the University of Queensland in Australia suggest that it is possible. But before examining the study in depth, it works to comprehend the development of the relationship between bacteria and antibiotics.

Given that the advanced discovery of penicillin by Alexander Fleming in 1928, antibiotics have been a vital tool in the fight versus bacteria and infections. And although we still use the same proven methods today, bacteria have progressed. When exposed to antibiotics, specific bacteria, fungi and parasites have the ability to adjust and cancel the efficiency of the drug by establishing resistance.

It’s worth pointing out that antimicrobial resistance was most likely to occur anyway, as the genetic code for bacteria changes with time. However, it is believed that the overuse of antibiotics is an important aspect that speeds up the development of resistant pressures.

According to the World Health Organization, antimicrobial resistance “is a progressively serious threat to international public health that requires action in all sectors of federal government and in society.” This has actually led scientists to believe outside the box by trying to recognize compounds that could be beneficial in the fight versus damaging bacteria. Among these compounds is cannabidiol (CBD), a cannabinoid found in Cannabis sativa.

Researchers are looking for new methods to assault infections and resistant bacteria.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD works versus Gram-positive bacteria. Stress of Gram-positive bacteria consist of Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich provided his findings at an annual meeting of the American Society for Microbiology. In vitro samples of both types of gram-positive bacteria were treated with synthetic CBD. The results led Dr. Blaskovich to the conclusion that CBD operates at levels similar to those of prescription antibiotics vancomycin and daptomycin. He likewise found that CBD appeared to work against gram-positive pressures of resistant bacteria, which numerous traditional antibiotics are starting to stop working.

” In particular, the activity was picked versus the resistant pressures of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low propensity to cause resistance and was active versus MRSA biofilms. “

The team likewise performed another study utilizing topical CBD to treat a skin infection in mice. Again, although the results were positive, CBD did not appear to get rid of the infection, however just to minimize the number of bacterial cells.

Could CBD end up being an antibiotic?

While it is simple to hail this work as a significant breakthrough in the anti-bacterial abilities of CBD, it is prematurely to quit on penicillin.

Although it is believed that the efficiency of simple CBD could come from the method it attacks the biofilm surrounding bacterial cells, the authors are still not sure of the mechanism of action of CBD. They likewise did not think twice to explain the drawbacks of the study. Dr. Blaskovich explained that considering that the results are in the initial phases, it is far too early for individuals to begin treating their CBD infections themselves.

The study was likewise performed in vitro (outside the body), and there is a risk that the results of medical trials will not be the same. Several compounds have revealed anti-bacterial efficacy in petri dishes, however then failed at this essential phase. It needs to likewise be mentioned that the two studies were performed in collaboration with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical eureka CBD products.

However, this research could be an important step forward for CBD and the fight versus antimicrobial resistance. CBD continues to have a great safety profile and is not considered hazardous even in large amounts. Thankfully, Dr. Blaskovich and his team strategy to continue their research.

Scroll to top